Use of guideline-concordant trimodality therapy is declining, with increasing trends toward de-escalation of locoregional treatment.
Guideline-Based Recommendations
Diagnosis
Identify IBC as a distinct clinical entity with aggressive behavior and poorer prognosis compared to non-IBC.
Management
Administer neoadjuvant chemotherapy as initial systemic treatment.
Perform modified radical mastectomy including resection of all involved skin without immediate breast reconstruction.
Conduct axillary lymph node dissection rather than sentinel lymph node biopsy for accurate staging and control.
Deliver postmastectomy radiation therapy to improve locoregional control and survival.
Monitoring & Follow-up
Monitor for locoregional recurrence given high risk in IBC.
Assess treatment response to neoadjuvant chemotherapy to guide surgical planning.
Risks
Avoid de-escalation of locoregional treatment as it is associated with increased risk of recurrence and inferior survival.
Be cautious about immediate breast reconstruction due to lack of evidence supporting safety in IBC.
Patient & Prescribing Data
Patients with stage III inflammatory breast cancer
Only about 25% receive guideline-concordant trimodality therapy; neoadjuvant systemic therapy is common but appropriate surgery and radiation are underutilized.
Clinical Best Practices
Ensure adherence to guideline-based trimodality therapy to optimize survival outcomes.
Avoid sentinel lymph node biopsy and immediate breast reconstruction in standard surgical management of IBC.
Consider emerging clinical trial data on neoadjuvant radiotherapy as a potential approach to improve quality of life without compromising oncologic outcomes.
Educate multidisciplinary teams on the distinct nature of IBC and the necessity of aggressive multimodal treatment.
